TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by US Bancorp DE

US Bancorp DE cut its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 20.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,818 shares of the biopharmaceutical company’s stock after selling 986 shares during the period. US Bancorp DE’s holdings in TG Therapeutics were worth $115,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its position in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the period. Synergy Asset Management LLC acquired a new position in TG Therapeutics during the fourth quarter worth $75,000. GAMMA Investing LLC raised its position in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,171 shares during the period. KBC Group NV raised its position in TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,092 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new position in TG Therapeutics during the third quarter worth $111,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 10.2 %

Shares of TGTX opened at $40.84 on Monday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $41.85. The firm has a 50-day moving average price of $31.86 and a 200 day moving average price of $29.08. The firm has a market capitalization of $6.41 billion, a P/E ratio of -408.36 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.50% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.